Skip to main content

Advertisement

SpringerLink
Log in

Alzheimer disease

Perceived efficacy of antidementia drug treatment

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

Investigators in Germany have solicited the views of neurologists and psychiatrists on the effectiveness of antidementia drug treatments. The study concludes that clinicians generally consider these treatments to be beneficial, and that the provision of support to caregivers seems to further enhance the perceived benefits.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Alzheimer's Society. Dementia UK report [online] (2007).

  2. National Institute for Health and Clinical Excellence. Alzheimer's disease—donepezil, galantamine, rivastigmine (review) and memantine [online] (2007).

  3. National Institute for Health and Clinical Excellence. Dementia: supporting people with dementia and their carers in health and social care [online] (2006).

  4. Waldemar, G. et al. Access to diagnostic evaluation and treatment for dementia in Europe. Int. J. Geriatr. Psychiatry 22, 47–54 (2007).

    Article  Google Scholar 

  5. Oude Voshaar, R. C., Burns, A. & Olde Rikkert, M. G. European Dementia Consensus Network Group (EDCON). Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. Int. J. Geriatr. Psychiatry 21, 29–31 (2006).

    Article  Google Scholar 

  6. Hallauer, J. F. Supply deficits in Alzheimer's disease [German]. Arzneimittel-Forschung (Drug Res.) 52, 4–12 (2002).

    Google Scholar 

  7. Riepe, M. W. & Ibach, B. Neurological and psychiatric practitioners' views on Alzheimer's disease and treatment thereof. Dement. Geriatr. Cogn. Disord. 26, 541–546 (2008).

    Article  CAS  Google Scholar 

  8. Department of Health. Living well with dementia: a National Dementia Strategy [online] (2009).

  9. Burns, A. & Iliffe, S. Alzheimer's disease. BMJ 338, b158 (2009).

    Article  Google Scholar 

  10. Burns, A. & Robert, P. The National Dementia Strategy in England. BMJ 338, b931 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Manchester Psychiatry Research Group, Manchester, UK

    Kevina McAvinchey & Alistair Burns

Authors
  1. Kevina McAvinchey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alistair Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alistair Burns.

Ethics declarations

Competing interests

K. McAvinchey declares no competing interests. A. Burns has acted as a consultant for Baxter, Eisai, Janssen-Cilag, Lundbeck, Novartis, Pfizer and Shire.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McAvinchey, K., Burns, A. Perceived efficacy of antidementia drug treatment. Nat Rev Neurol 5, 302–303 (2009). https://doi.org/10.1038/nrneurol.2009.56

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.56

  • Springer Nature Limited

Search

Navigation